|
The number of bacteriologically evaluable patients was comparable between the two dosing regimens. Augmentin produced comparable bacteriological success rates in patients assessed 2 to 4 days immediately following end of therapy. The bacteriologic efficacy rates were comparable at one of the follow-up visits (5 to 9 days post-therapy) and at a late post-therapy visit (in the majority of cases, this was 2 to 4 weeks post-therapy), as seen in the table below: 875 mg q12h 500 mg q8h 2 to 4 days 81%, n= 58 80%, n= 54 5 to 9 days 58.5%, n= 41 51.9%, n= 52 2 to 4 weeks 52.5%, n= 101 54.8%, n= 104 As noted before, though there was no significant difference in the percentage of adverse events in each group, there was a statistically significant difference in rates of severe diarrhea or withdrawals with diarrhea between the regimens. REFERENCES Text Continues Below
1. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically— Third Edition. Approved Standard NCCLS Document M7-A3, Vol. 13, No. 25. NCCLS, Villanova, PA, December 1993. 2. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests— Fifth Edition. Approved Standard NCCLS Document M2-A5, Vol. 13, No. 24. NCCLS, Villanova, PA, December 1993. 3. Swanson-Biearman B, Dean BS, Lopez G, Krenzelok EP. The effects of penicillin and cephalosporin ingestions in children less than six years of age. Vet Hum Toxicol 1988; 30: 66-67. DATE OF ISSUANCE MAY 2002
©2002, GlaxoSmithKline All rights reserved. GlaxoSmithKline Research Triangle Park, NC 27709
AG: AL10 INDICATIONS AND USAGE Augmentin is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Page: << Prev | 1 | 2 | 3 | 4 | 5 | Next >>
|
.gif)
